Axsome Therapeutics has built a portfolio of differentiated product candidates that address areas of high unmet medical needs.

Our pipeline includes four differentiated clinical-stage central nervous system (CNS) therapies targeting significant and growing markets.

Abbreviations: CNS = Central Nervous System; MOA = Mechanism of Action; NMDA = N-Methyl-D-aspartate; COX-2 = Cyclooxygenase-2; 5-HT = 5-Hydroxytryptamine;
NE = Norepinephrine

The investigational product candidates on this page are not approved by the FDA and the safety and effectiveness has not been established.

Expanded Access Policy